Subscribe to RSS
Download PDF
DOI: 10.1055/s-0042-1743422
Influence of New FIGO 2018 Staging on Treatment Outcomes in Early-Stage Cervical Cancer: A Single-Center Study
Funding Nil.
Abstract
Purpose The aim of this article was to study survival outcomes of early-stage cervical cancer patients and impact on survival after restaging them as per International Federation of Gynecology and Obstetrics (FIGO) 2018.
Materials and Methods A retrospective study was conducted from June 1, 2013 to May 31, 2018 in a tertiary care hospital in North India. One-hundred patients of early-stage cervical cancer (as per FIGO 2009 staging) who had been treated by surgery followed by risk based tailored adjuvant therapy in our hospital were evaluated. The clinicopathological features and survival outcomes of these patients were analyzed. These patients were then restaged as per new FIGO 2018 staging and survival outcomes between two FIGO classifications were compared.
Results The median age of the study population was 52.5 years with median follow-up of 62.1 months. Ninety percent of our patients had more than 2 years follow-up and 59% had more than 5 years follow-up. The overall survival and relapse-free survival were 87.5 and 91.4%, respectively. The study population was then reclassified according to new FIGO 2018 staging. It was seen that the patients with stage IB1and IB2 cervical cancer had overall survival of 91.1 and 90%, respectively. The overall survival of stage IB3 was 80% and the survival of stage IIIC1 was only 60%.
Conclusion The new FIGO 2018 classification has a significant effect on survival outcome and in prognostication of patients with cervical cancer.
Ethical Approval
Ethical committee approval from hospital ethics board taken.
Publication History
Article published online:
25 June 2022
© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143 (Suppl. 02) 22-36
- 2 Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol 1999; 73 (02) 177-183
- 3 Zeng J, Qu P, Hu Y. et al. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: a single center retrospective study. Medicine (Baltimore) 2020; 99 (16) e19714
- 4 de Gregorio A, Widschwendter P, Ebner F. et al. Influence of the new FIGO classification for cervical cancer on patient survival: a retrospective analysis of 265 histologically confirmed cases with FIGO stages IA to IIB. Oncology 2020; 98 (02) 91-97
- 5 Berek JS, Matsuo K, Grubbs BH. et al. Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. J Gynecol Oncol 2019; 30 (02) e40
- 6 Grigsby PW, Massad LS, Mutch DG. et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival. Gynecol Oncol 2020; 157 (03) 639-643
- 7 Thomas V, Chandy RG, Sebastian A. et al. Treatment outcomes of early carcinoma cervix before and after sub-specialization. Indian J Surg Oncol 2021; 12 (01) 78-85